drugset / Trial / NCT01122407
Pathophysiology of Cardiometabolic Risk Factors in African Americans
Phase 1
Completed
34 enrolled
Vanderbilt University Medical Center
National Heart, Lung, and Blood Institute (NHLBI) · collab
Non-randomizedSingle-groupOpen-label
Summary
The overall goal of this proposal is to determine the autonomic and nitric oxide contribution in the pathogenesis of hypertension and insulin resistance in obese African American women. For this purpose we will use two non-FDA approved drugs: Trimethaphan IND# 63826 Approval date 12/20/2001 L-NMMA IND# 41735 Approval date 09/1993
Timeline
- Start
- 2010-01
- Primary completion
- 2016-11
- Completion
- 2016-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | L-NMMA | Unknown | 250 ug/kg | — |
| Subject | Trimethaphan | Small molecule | 4 mg | — |